PXT 3003 is in phase 3 clinical trials for the treatment of Charcot-Marie-Tooth disease type 1A in adults.
PXT 3003 is in phase 3 clinical trials for the treatment of Charcot-Marie-Tooth disease type 1A in adults.
No indication information available.
No associated conditions information available.
Stay informed with timely notifications on clinical trials and research advancements.